All data are based on the daily closing price as of November 20, 2025
h
Hisamitsu Pharmaceutical
4530.TSE
26.16 USD
-0.94
-3.47%
Overview
Last close
26.16 usd
Market cap
1.84B usd
52 week high
32.23 usd
52 week low
22.74 usd
Target price
27.51 usd
Valuation
P/E
15.6542
Forward P/E
N/A
Price/Sales
1.9107
Price/Book Value
1.107
Enterprise Value
1.17B usd
EV/Revenue
1.1824
EV/EBITDA
5.6607
Key financials
Revenue TTM
989.08M usd
Gross Profit TTM
590.80M usd
EBITDA TTM
158.14M usd
Earnings per Share
1.71 usd
Dividend
0.56 usd
Total assets
334.93B usd
Net debt
-101.46B usd
About
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as, external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asia, the United States, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.